玻璃体腔内注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察被引量：8

Curative Effect Analysis on Intra Vitreous Injection of Conbercept in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

在线阅读下载PDF

导出

摘要目的总结视网膜静脉阻塞(retinal vein occlusion,RVO)继发黄斑水肿疾病玻璃体腔内注射康柏西普治疗方案,评价玻璃体腔内注射康柏西普治疗的疗效及安全性。方法回顾性分析2019年5月至2020年3月期间在我院确诊为RVO继发黄斑水肿并接受玻璃体腔内注射康柏西普治疗的患者。其中视网膜中央静脉阻塞(CRVO)16例(16眼);视网膜分支静脉阻塞(BRVO)32例(32眼);病程3 d^12个月,年龄33~84岁,平均62.4岁;向玻璃体腔内注射康柏西普眼用注射液0.5 mg/0.05 mL,比较治疗期间最佳矫正视力以及黄斑中心凹视网膜厚度变化情况。结果48例(48眼)患者,其中注射1次20眼(41.67%),注射2次12眼(25%),注射3次8眼(16.67%),注射4次8眼(16.67%)。治疗前及治疗后1 w、2 w、1个月、3个月患者的最佳矫正视力(标准化logMAR)分别为0.891±0.451、0.454±0.336、0.391±0.364、0.438±0.358、0.509±0.317,治疗后明显提高(P<0.05)。治疗前患眼黄斑中心凹视网膜厚度为(489.06±136.72)μm;治疗后1 w黄斑中心凹视网膜厚度为(288.98±50.89)μm;治疗后2 w黄斑中心凹视网膜厚度为(246.32±50.62)μm;治疗后1个月黄斑中心凹视网膜厚度为(344.77±84.23)μm;治疗后3个月黄斑中心凹视网膜厚度为(351.33±95.70)μm,治疗后黄斑水肿与治疗前相比(P<0.05);治疗后2眼局部球结膜下出血,未见严重不良反应发生。结论玻璃体腔内注射康柏西普可以明显改善和提高视网膜静脉阻塞继发黄斑水肿患者的视力,患者眼压正常,且安全性获得保障。 Objective To evaluate the efficacy and safety of intravitreal injection of conbercept in the treatment of macular edema secondary to retinal vein occlusion(retinal vein occlusion,RVO).Methods Patients of RVO with macular edema who were diagnosed in our hospital from May 2019 to March 2020 and received intravitreal injection of conbercept were analyzed retrospectively.There were 16 cases of central retinal vein occlusion(CRVO)and 32 cases of branch retinal vein occlusion(BRVO)and the course of disease ranged from 3 days to 12 months,and the age ranged from 33 to 84,with an average age of 62.4.Conbercept intraocular injection(0.5 mg/0.05 mL)was given into the vitreous cavity and then the best corrected visual acuity and the changes of retinal thickness in macular fovea during treatment were compared.Results Among 48 patients(48 eyes),20 eyes were injected once(41.67%),12 eyes were injected twice(25%),8 eyes were injected three times(16.67%),and 8 eyes were injected four times(16.67%).The best corrected visual acuity(standardized logMAR)before treatment and 1 week,2 weeks,1 month and 3 months after treatment was 0.891±0.451,0.454±0.336,0.391±0.364,0.438±0.358 and 0.509±0.317 respectively,with significant improvement after treatment(P<0.05).The retinal thickness of eye macular center concave before treatment and 1 week,2 weeks,1 month and 3 months after treatment was 489.06±136.72 microns,288.98±50.89 microns,246.32±50.62 microns,344.77±84.23 microns and 351.33±95.70 microns,and the difference before and after treatment was statistically significant(P<0.05).There was local subconjunctival hemorrhage in 2 eyes after treatment,without serious adverse reactions.Conclusion Intravitreal injection of conbercept can significantly improve the visual acuity of patients with macular edema secondary to retinal vein occlusion,and furthermore,the security is guaranteed.

作者李洪生刘华 Li Hongsheng;Liu Hua(Jinzhou Medical University,Jinzhou 121000 China)

机构地区锦州医科大学

出处《锦州医科大学学报》 CAS 2020年第4期38-41,共4页 Journal of Jinzhou Medical University

关键词视网膜静脉阻塞黄斑水肿玻璃体腔注药术康柏西普 retinal vein occlusion macular edema vitreous cavity injection conbercept

分类号 R774.1 [医药卫生—眼科]

作者简介李洪生(1982),男,辽宁东港人,副主任医师,硕士学位,主要研究方向为眼底病;通讯作者:刘华(1963),女,辽宁锦州人,教授,博士学位,主要研究方向为年龄相关性眼病。

引文网络
相关文献

参考文献5

1王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471-473. 被引量：37
2史春生,姜波.康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗视网膜分支静脉阻塞性黄斑水肿22例[J].安徽医药,2020,24(2):296-300. 被引量：28
3闫忠阳,冬敏,杨娜,李雅琳,李成泉,王莉菲.康柏西普玻璃体腔注射治疗糖尿病视网膜病变伴黄斑水肿的临床效果[J].山东医药,2017,57(37):57-59. 被引量：26
4胡永成,张智科,张萍,贾瑞清,贾金生,景淑贞,张旭东.康柏西普联合眼底激光治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J].中国实用眼科杂志,2018,36(6):423-425. 被引量：6
5王华,席亚慧,沈兰珂,贺春香.玻璃体腔注射康柏西普对黄斑水肿患者角膜厚度和内皮细胞的影响[J].国际眼科杂志,2019,19(4):657-659. 被引量：7

二级参考文献24

1ROUVAS A, PETROU P, NTOURAKI A, DOUVALI M, LADAS I, VERGADOS I. Intravitreal ranibizumab ( lucentis ) for branch retinal vein occlusion-induced macular edema: Nine- month results of a prospective study [J]. Retina, 2010,30 (6) :893-902.
2NOMA H, FUNATSU H, MIMURA T, EGUCH1 S. Vascular en- dothelial growth factor receptor-2 in macular oedema with retinal vein occlusion I J]- Ophthalmic Res, 2012,48 (l) :56- 58.
3MCINTOSH RL, ROGERS SL, LIM L, CHEUNG N, WANG J J, MITCHELL P, et al. Natural history of central retinal vein oc- clusion: An evidence-based systematic review [J]. Ophthal- mology,2010,117(6) :1113-1123.
4ROGERS SL, MCINTOSH RL, LIM L, MITCHELL P, CHEUNG N, KOWALSKI JW, et al. Natural history of branch retinal vein occlusion: An evidence-based systematic review [J]. Oph- thalmology ,2010,117 ( 6 ) : 1094-1101.
5PATZ A. Argon laser photocoagulation for macular edema in branch vein occlusion [ J]. Ant J Ophthalmol, 1984,98 ( 3 ) : 374-375.
6PECE A, ISOLA V, PIERMAROCCHI S, CALORI G. Efficacy and safety of anti-vascular endothelial growth factor (vegf) therapy with intravitreal ran~bizuinab (lueentis) for naive retinal vein occlusion: 1-year follow-up [ J ]. Br d Ophthal- mol,2011,95 ( 1 ) :56-68.
7BROWN DM, CAMPOCHIARO PA, BHISITKUL RB, ttO AC, GRAY S, SAROJ N, et al. Sustained benefits from ranibizumab for maeular edema following branch retinal vein occlusion: 12-month outcomes of a phase iii study~ J]. Ophtholmology, 2011,118(8) :1594-1602.
8CAMPOCHIARO PA, HAFIZ G, CHANNA R, SHAH SM, NGUY- EN QD, YING H, et al. Antagonism of vascular endothelial growth factor for maeular edema caused by retinal vein oc- clusions: Two-year outcomes I J 1. Ophthalmology, 2010,117 (12) :2387-2394.
9YU DC, LEE JS, YOO JY, SHIN H, DENG H, WEI Y, et al. Soluble vascular endothelial growth factor decoy receptor fp3 exerts potent antiangiogenic effects[J]. Mol Ther,2012, 20 ( 5 ) : 938 -947.
10LI X, XU G, WANG Y, XU X, LIU X, TANG S, et al. Safety and efficacy of conbercept in neovascular age-related macu- lar degeneration : Results from a 12-month randomized phase 2 study: Aurora study[J].Ophthalmology, 2014, 121 ( 9 ) : 1740-1747.